tirzepatide surmount 4 for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Just sharing the published Surmount

By promoting weight loss, semaglutide may help reduce the risk and severity of these obesity-related conditions, leading to improved overall health outcomes

Dahl D, Onishi Y, Norwood P et al (2022) Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial

There is a broad consensus that GLP-1 receptor agonists have transformed the management of T2D, obesity, and related morbidity and have been associated with reduced progression of renal disease, cardiovascular disease, and mortality in people with metabolic disorders

It plays a crucial role in detoxification, immune defense, and antioxidant protection

She highlighted prescriber-directed medication adjustmentssuch as slow dose escalation, use of the lowest therapeutic dose, microdosing/intermediate dosing, and supportive measures, such as anti-emetics/prokineticsas effective strategies for side-effect management